Swindon’s Wasdell Group has announced it will build a new pharmaceutical packaging, testing and distribution facility in Dundalk, Ireland in order to support further expansion throughout Ireland and Europe.
The decision was made in order to maintain a foothold in Europe in light of further Brexit developments.
The new facility will enable the company to continue its work around clinical trials packing, primary and secondary packaging, and distribution of biopharmaceutical products.
Wasdell also offers contract manufacturing services with FDA and MHRA approved analytical and microbiology laboratories, and this 70,000 sq ft new facility will be the company’s EU hub for Qualified Persons pharmaceutical release, analytical testing, primary and secondary pharmaceutical packaging and distribution.
The new facility has been supported by the Irish Government through IDA Ireland.
Martin Tedham, Managing Director of Wasdell Group, said: “This is an exciting opportunity for the Wasdell Group and specifically the Wasdell Packaging division. We have always had a strong customer base in Ireland and we are certain that this trend will continue, particularly with the impending Brexit situation as companies typically from the UK and USA look to securing a base to service their European markets.
“As a business we have always been ready to change and flex according to our market and customers’ need. As we continue to be affected by global changes and Brexit, we need to respond and develop. This site in Ireland allows us to maintain a strong position in Europe should Brexit continue on course and also meet the ongoing rate of growth we are seeing in Ireland.
“We remain committed to Swindon and have plans to continue our growth in the town and to be a dynamic contributor to local employment and the wider economy. This expansion will have a very positive knock-on effect to our Wiltshire headquarters, everyone who works for Wasdell and all of our local suppliers.”